1.79 USD
↗ 0.00 (0.00%)AT CLOSE (11:59 AM EDT)
Allogene Therapeutics, Inc. Common Stock
ALLONASDAQ • USD
1.80
↗ 0.01 (0.34%)
POST MARKET (AS OF 07:22 PM EDT)
Post Market
AS OF 07:22 PM EDT
1.80
↗ 0.01 (0.34%)
Market: CLOSED
Allogene Therapeutics, Inc. Common Stock (ALLO) trades at $1.81 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics suggest ALLO is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Jul 17, 2026.
Open?$1.75
High?$1.83
Low?$1.74
Prev. Close?$1.79
Volume?4.9M
Avg. Volume?9.8M
VWAP?$1.80
Rel. Volume?0.50x
Bid / Ask
Bid?$1.53 × 100
Ask?$2.07 × 100
Spread?$0.54
Midpoint?$1.80
Valuation & Ratios
Market Cap?617.8M
Shares Out?345.2M
Float?170.0M
Float %?69.4%
P/E Ratio?N/A
P/B Ratio?2.22
EPS?-$0.50
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Themes
Employees
152
Market Cap
617.8M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2018-10-11
Address
210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 457-2700
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 457-2700
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?77
Short Sent.?13
Piotroski F-Score?0/9Weak
Altman Z-Score?-4.94Distress
Confidence?46%Low
Short InterestSqueeze Risk
Short % of Float?37.30%Squeeze Risk
Short Interest?63.4M
Days to Cover?5.1
Free Float170.0M
Avg Daily Volume12.3M
Settlement Date2026-06-30
Financial Health
Current Ratio?9.65Strong
Quick Ratio?9.65Strong
Cash Ratio?1.07Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?2.22CHEAP▾
Peers100
S&P69
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-3.3CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-62.3%WEAK▾
S&P3
ROA?-43.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-109526000
Enterprise Value?$587.5M
Fundamentals ratios updated end of day